Login / Signup

Zanubrutinib plus cytarabine in patients with refractory/relapsed primary central nervous system lymphoma.

Zhiguang LinJingjing MaYan MaQing LiHui KangMengxue ZhangBobin Chen
Published in: Acta haematologica (2024)
Zanubrutinib and cytarabine showed efficacy in r/r PCNSL with an acceptable safety profile.
Keyphrases
  • acute myeloid leukemia
  • diffuse large b cell lymphoma
  • high dose
  • cerebrospinal fluid
  • low dose